Karyopharm Therapeutics Stock Performance
| KPTI Stock | USD 4.59 0.05 1.08% |
The company secures a Beta (Market Risk) of 0.92, which conveys possible diversification benefits within a given portfolio. Karyopharm Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Karyopharm Therapeutics is expected to follow. At this point, Karyopharm Therapeutics has a negative expected return of -0.73%. Please make sure to verify Karyopharm Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Karyopharm Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (1.08) | Five Day Return (13.23) | Year To Date Return (62.28) | Ten Year Return (98.86) | All Time Return (98.09) |
Last Split Factor 1:15 | Last Split Date 2025-02-26 |
1 | Acquisition by Mano Michael of 4500 shares of Karyopharm Therapeutics at 7.95 subject to Rule 16b-3 | 02/28/2025 |
2 | Disposition of 2793 shares by Mano Michael of Karyopharm Therapeutics at 6.29 subject to Rule 16b-3 | 03/04/2025 |
3 | Acquisition by Mirza Mansoor Raza of 69000 shares of Karyopharm Therapeutics at 0.96 subject to Rule 16b-3 | 03/10/2025 |
4 | Acquisition by Mano Michael of 9167 shares of Karyopharm Therapeutics subject to Rule 16b-3 | 03/28/2025 |
5 | Disposition of 245 shares by Paulson Richard A. of Karyopharm Therapeutics at 3.74 subject to Rule 16b-3 | 04/04/2025 |
6 | Disposition of 419 shares by Rangwala Reshma of Karyopharm Therapeutics at 6.17 subject to Rule 16b-3 | 04/23/2025 |
7 | Disposition of 236 shares by Paulson Richard A. of Karyopharm Therapeutics at 7.12 subject to Rule 16b-3 | 05/06/2025 |
8 | Karyopharm Therapeutics Q1 Earnings Snapshot | 05/12/2025 |
9 | Barclays Updates Karyopharm Price Target, Eyes Future Data KPTI Stock News | 05/13/2025 |
10 | Karyopharm Therapeutics Inc. Q1 2025 Earnings Call Transcript | 05/14/2025 |
11 | Royal Bank of Canada Cuts Karyopharm Therapeutics Price Target to 33.00 | 05/16/2025 |
12 | Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference KPTI ... | 05/19/2025 |
| Begin Period Cash Flow | 53.2 M |
Karyopharm | Build AI portfolio with Karyopharm Stock |
Karyopharm Therapeutics Relative Risk vs. Return Landscape
If you would invest 893.00 in Karyopharm Therapeutics on February 24, 2025 and sell it today you would lose (434.00) from holding Karyopharm Therapeutics or give up 48.6% of portfolio value over 90 days. Karyopharm Therapeutics is currently does not generate positive expected returns and assumes 7.5711% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Karyopharm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Karyopharm Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Karyopharm Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Karyopharm Therapeutics, and traders can use it to determine the average amount a Karyopharm Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0967
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KPTI |
Estimated Market Risk
| 7.57 actual daily | 67 67% of assets are less volatile |
Expected Return
| -0.73 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Karyopharm Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Karyopharm Therapeutics by adding Karyopharm Therapeutics to a well-diversified portfolio.
Karyopharm Therapeutics Fundamentals Growth
Karyopharm Stock prices reflect investors' perceptions of the future prospects and financial health of Karyopharm Therapeutics, and Karyopharm Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Karyopharm Stock performance.
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.45 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (1.11) % | ||||
| Current Valuation | 156.42 M | ||||
| Shares Outstanding | 8.64 M | ||||
| Price To Earning | (3.90) X | ||||
| Price To Book | 12.05 X | ||||
| Price To Sales | 0.28 X | ||||
| Revenue | 145.24 M | ||||
| Gross Profit | 137.54 M | ||||
| EBITDA | (38.6 M) | ||||
| Net Income | (76.42 M) | ||||
| Cash And Equivalents | 170.85 M | ||||
| Cash Per Share | 2.14 X | ||||
| Total Debt | 194.52 M | ||||
| Debt To Equity | 2.59 % | ||||
| Current Ratio | 3.88 X | ||||
| Book Value Per Share | (24.03) X | ||||
| Cash Flow From Operations | (127.49 M) | ||||
| Earnings Per Share | (11.87) X | ||||
| Market Capitalization | 39.66 M | ||||
| Total Asset | 164.42 M | ||||
| Retained Earnings | (1.56 B) | ||||
| Working Capital | 64.23 M | ||||
| Current Asset | 130.25 M | ||||
| Current Liabilities | 14.95 M | ||||
About Karyopharm Therapeutics Performance
By evaluating Karyopharm Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Karyopharm Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Karyopharm Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Karyopharm Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 287.95 | 221.10 | |
| Return On Tangible Assets | (0.46) | (0.49) | |
| Return On Capital Employed | (1.66) | (1.57) | |
| Return On Assets | (0.46) | (0.49) | |
| Return On Equity | 0.41 | 0.43 |
Things to note about Karyopharm Therapeutics performance evaluation
Checking the ongoing alerts about Karyopharm Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Karyopharm Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Karyopharm Therapeutics generated a negative expected return over the last 90 days | |
| Karyopharm Therapeutics has high historical volatility and very poor performance | |
| Karyopharm Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (76.42 M) with profit before overhead, payroll, taxes, and interest of 137.54 M. | |
| Karyopharm Therapeutics currently holds about 170.85 M in cash with (127.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14. | |
| Latest headline from news.google.com: Day one Biopharmaceuticals officer sells 24,574 in stock - Investing.com |
- Analyzing Karyopharm Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Karyopharm Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Karyopharm Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Karyopharm Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Karyopharm Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Karyopharm Therapeutics' stock. These opinions can provide insight into Karyopharm Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |